Clinical trials: Skin Diseases, Papulosquamous
Rheumatoid Arthritis, Psoriatic Arthritis
A Study To Evaluate The Efficacy Of Enbrel (REGISTERED) Etanercept Over A Period Of 12 Months In The Routine Treatment Of Patients With Rheumatoid Arthritis, Axial Spondyloarthritis, Psoriatic Arthritis, Or Plaque Psoriasis.
The purpose of this non-interventional study is to evaluate the efficacy of etanercept during routine clinical use over a maximum of 12 months in patients with rheumatoid arthritis (RA), psoriatic arthritis(PsA), axial…
- Conditions
- Rheumatoid Arthritis, Psoriatic Arthritis, Axial Spondyloarthritis, Plaque Psoriasis
- Trial name
- ADEQUATE (NCT02486302)
- Testing
- Etanercept
- Where
- 180 sites in Germany
- Volunteers
- 1,534 people
- Sponsor
- Pfizer
Rheumatoid Arthritis, Psoriatic Arthritis
INSELMA - a Randomised Controlled Trial
Background: Patients with inflammatory arthritis (IA) experience substantial impact of their disease despite optimal pharmacological treatment.
- Conditions
- Rheumatoid Arthritis, Psoriatic Arthritis, Axial Spondyloarthritis
- Trial name
- INSELMA-RCT (NCT06583980)
- Testing
- Interdisciplinary Nurse-coordinated self-management support for people with inflammatory arthritis and substantial disease impact
- Where
- 3 sites in Denmark
- Volunteers
- 120 people
- Sponsor
- The Danish Center for Expertise in Rheumatology
Psoriasis
Pharmacokinetic, Safety, Tolerability, and Immunogenicity Comparison of CKD-704 (Risankizumab Biosimilar), With EU-approved Skyrizi®, and US-licensed Skyrizi® in Healthy Adult Participants
This is a Phase 1, first-in-human (FIH), randomized, double-blind, single-dose, parallel-group, 3-arm study to compare PK, safety, tolerability, and immunogenicity profiles of CKD-704, EU-approved Skyrizi, and US-licensed Skyrizi…
- Trial name
- NCT07258745
- Testing
- SKYRIZI, CKD-704
- Where
- Poland
- Volunteers
- 213 people, healthy volunteers welcome
- Sponsor
- Chong Kun Dang Pharmaceutical
Plaque Psoriasis, Psoriasis
Safety and Efficacy Study of Etanercept (Qiangke®) to Treat Moderate to Severe Plaque Psoriasis
This is a randomized, double-blind, multicentral clinical trial to investigate the efficacy and safety of Recombinant Human TNF Receptor-Ig Fusion Protein for Injection (Qiangke®) in the treatment of Moderate to Severe Plaque…
- Trial name
- NCT02701205
- Testing
- etanercept, etanercept (half dose)
- Where
- 4 sites in China
- Volunteers
- 216 people
- Sponsor
- Shanghai Celgen Bio-Pharmaceutical Co.,Ltd
Atopic Dermatitis, Psoriasis
Clinical, Psychological and Genetic Characteristics in Dermatological Patients
Atopic dermatitis (AD) and psoriasis (PS) are chronic, relapsing dermatological disorders with a high rate of psychiatric co-morbid pathology represented with depression.
- Trial name
- NCT03831646
- Where
- Kazakhstan
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- Astana Medical University
Psoriatic Arthritis
Validation of Handheld Ultrasound Devices in Rheumatology
The goal of this clinical trial is to test the concurrent validity of the Clarius handheld ultrasound devices versus gold-standard device to detect characteristic features of healthy and rheumatic joints in adults Psoriatic…
- Trial name
- NCT06580886
- Testing
- Ultrasound
- Where
- 3 sites in United States, Canada
- Volunteers
- 30 people
- Sponsor
- Ottawa Hospital Research Institute
Systemic Lupus Erythematosus, Arthritic Psoriasis
The Effect of BMS-986165 Combined With an Oral Contraceptive (Ethinyl Estradiol/Norethindrone) in Healthy Female Patients
The purpose of this study is to investigate the effect of BMS-986165 in combination with an oral contraceptive in healthy female patients.
- Conditions
- Systemic Lupus Erythematosus, Arthritic Psoriasis, Psoriasis, Inflammatory Bowel Diseases
- Trial name
- NCT03262727
- Testing
- BMS-986165, Loestrin 1.5/30 (1.5 mg norethindrone acetate/30 μg ethinyl estradiol)
- Where
- United States
- Volunteers
- 49 people, healthy volunteers welcome
- Sponsor
- Bristol-Myers Squibb
Psoriasis
Role of Brodalumab in the Modulation of Gut Microbiome in Psoriatic Patients
BOMOGUMIP is an interventional research with minimal risk and constraints (cat.2), exploratory, intra-individual, prospective, multi-site study.
- Trial name
- BOMOGUMIP (NCT04680624)
- Testing
- Fecal sample collection
- Volunteers
- 15 people
- Sponsor
- Association pour la Recherche Clinique et Immunologique
Seborrheic Dermatitis
Efficacy and Safety of ASF1057 in the Treatment of Seborrhoeic Dermatitis
A growing body of evidence supports the hypothesis that the pathophysiology of seborrhoeic dermatitis has a potentially causative neurogenic inflammatory aspect.
- Trial name
- NCT00565279
- Testing
- ASF1057
- Volunteers
- 300 people
- Sponsor
- Astion Pharma A/S
Psoriasis
Evaluate Safety and Tolerability of Calcipotriene Foam 0.005% in Pediatric Subjects With Mild/Moderate Plaque Psoriasis
Calcipotriene is a vitamin D3 analog that has been used as topical therapy in adult subjects with plaque-type psoriasis since 1993.
- Trial name
- NCT01582932
- Testing
- Calcipotriene 0.005% Foam
- Where
- 36 sites in United States
- Volunteers
- 36 people
- Sponsor
- Mayne Pharma International Pty Ltd
Psoriasis
A Study of the Efficacy and Safety of DFD-06 Cream in the Treatment of Moderate to Severe Plaque Psoriasis
This study will compare the efficacy and safety of DFD-06 Cream to Vehicle Cream for topical treatment of moderate to severe plaque psoriasis after 3, 7, and 14 days of treatment.
- Trial name
- NCT02635204
- Testing
- DFD06 Cream, Vehicle Cream
- Where
- 30 sites in United States
- Volunteers
- 267 people
- Sponsor
- Promius Pharma, LLC
Inflammatory Arthritis, Ankylosing Spondylitis
Impact of Barriers and Facilitators to Physical Activity in Patients With Inflammatory Arthritis
Background: Patients with inflammatory arthritis (IA), such as spondyloarthritis (axSpA), rheumatoid arthritis (RA) or psoriatic arthritis (PsA) are more prone to physical inactivity but derive specific benefits from regular…
- Conditions
- Inflammatory Arthritis, Ankylosing Spondylitis, Rheumatoid Arthritis, Psoriatic Arthritis
- Trial name
- ImBAIA (NCT04426747)
- Testing
- No intervention
- Where
- France
- Volunteers
- 200 people
- Sponsor
- Groupe Hospitalier Pitie-Salpetriere
Plaque Psoriasis
Tapinarof for the Treatment of Plaque Psoriasis in Adults (3001)
This is a randomized, double-blind, vehicle-controlled Phase 3 study to evaluate the efficacy and safety of topical tapinarof cream, 1% once daily for the treatment of plaque psoriasis in adults.
- Trial name
- NCT03956355
- Testing
- Tapinarof, Vehicle Cream
- Where
- 53 sites in United States, Canada
- Volunteers
- 510 people
- Sponsor
- Organon and Co
Psoriasis
Observational Study Evaluating Etanercept (Enbrel®) In Subjects With Plaque-Type Psoriasis In Usual Care Settings
This prospective observational cohort study will assess the average duration of the drug free interval between etanercept treatment cycles in usual care settings in Germany.
- Trial name
- NCT00708708
- Testing
- etanercept (Enbrel®)
- Where
- Germany
- Volunteers
- 926 people
- Sponsor
- Pfizer
Psoriasis, Coronary Artery Disease
Premature Coronary Artery Disease (CAD) in Severe Psoriasis
The purpose of this study is to compare the prevalence and severity of CAD (coronary artery disease) in patients with and without severe psoriasis, otherwise matched for cardiovascular risk factors.
- Trial name
- NCT00893126
- Testing
- CCTA Scan (Coronary CT Angiogram)
- Where
- United States
- Volunteers
- 46 people, healthy volunteers welcome
- Sponsor
- University of Michigan
Psoriasis
Study of the Effects of the Organism on Monomethyl Fumarate (MMF) After the Administration of LAS41008
The purpose of this study is to determine how the organism affects MMF (metabolite of dimethyl fumarate [DMF]) after single oral dose administration of LAS41008 120 mg gastroresistant tablet and Fumaderm® 120 mg gastro-resistant…
- Trial name
- LAS41008 (NCT02955693)
- Testing
- LAS41008 120 mg / Fumaderm® 120 mg
- Where
- United Kingdom
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Almirall, S.A.
Actively Extending Plaque Psoriasis, Moderate to Severe Plaque Psoriasis
Trial of IMO-3100 in Patients With Moderate to Severe Plaque Psoriasis
The purpose of this study is to evaluate different dose levels of IMO-3100 compared to placebo administered for 4 weeks to patients with moderate to severe plaque psoriasis.
- Trial name
- NCT01622348
- Testing
- IMO-3100 at 0.16 mg/kg, Saline for Injection, IMO-3100 at 0.32 mg/kg
- Where
- 13 sites in United States
- Volunteers
- 44 people
- Sponsor
- Idera Pharmaceuticals, Inc.
Seborrheic Dermatitis
Safety and Efficacy of a Topical Cream in Mild-to-Moderate Seborrheic Dermatitis
A Randomized, Double-Blind, Placebo-Controlled Clinical Study to Evaluate the safety and efficacy of scalp cream for Symptom Relief and Microbiome Balance in mild-moderate Seborrheic Dermatitis patients.
- Trial name
- NCT07063615
- Testing
- Microbiome-Powered Cream
- Where
- India
- Volunteers
- 34 people
- Sponsor
- NovoBliss Research Pvt Ltd
Psoriatic Arthritis (PsA)
Preventing Structural Damage in Early Psoriatic Arthritis
Investigators hypothesize that TNFi is superior to SC MTX in preventing structural damage in early, treatment-naïve PsA, assessed using HR-pQCT.
- Trial name
- NCT07486843
- Testing
- Amgevita 40Mg Solution for Injection, Methotrexate (Metoject® prefilled pen)
- Where
- Hong Kong
- Volunteers
- 108 people
- Sponsor
- Chinese University of Hong Kong
Psoriatic Arthritis
Efficacy and Safety of HS-10374 Compared to Placebo in Adults With Active Psoriatic Arthritis
This study has been designed to explore the clinical efficacy and safety of HS-10374 in the treatment of active psoriatic arthritis.
- Trial name
- NCT06176508
- Testing
- HS-10374, Tofacitinib 5Mg Tab,Oral
- Where
- China
- Volunteers
- 160 people
- Sponsor
- Hansoh BioMedical R&D Company
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.